Date: 2015-03-19
Type of information: Initiation of preclinical development
phase: preclinical
Announcement: initiation of preclinical development
Company: Vect-Horus (France)
Product: VH-N439
Action
mechanism: peptide analog. Neurotensin is a neuropeptide with global hypothermic potential when administered directly into the brain, but unable to cross the blood-brain barrier (BBB) when administrated alone systemically. Vect-Horus has developed VH-N439, a new chemical entity based on the conjugation of one of its peptide-vectors to an analogue of neurotensin.
Disease: therapeutic hypothermia
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
Country:
Trial details:
Latest
news: * On March 19, 2015, Vect-Horus, a biotechnology company that designs and develops peptide-vectors to facilitate the delivery of drugs or imaging agents, notably in the brain, announced the start of regulatory preclinical development of its candidate VH-N439, a
conjugated form of neurotensin for therapeutic hypothermia. Using in vivo models, the company has already shown improved potent hypothermia effects of VH-N439 compared to those obtained with free neurotensin. Interestingly, when it is administered by intravenous perfusion, VH-N439 induced a hypothermic effect that was maintained for several hours. This longduration effect is of great interest since a long-term hypothermia is essential to treat patients following cardiac arrest or neonatal hypoxia/ischemia. The company intends to start Phase 1 clinical trials early 2016. Alexandre Tokay, CEO, added: “VH-N439 could be positioned as a first-in-class neuroprotective agent following sudden cardiac arrest and neonatal hypoxia/ischemia\".
